S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
Status:
Withdrawn
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop
the growth of tumor cells by blocking blood flow to the tumor. Giving capecitabine and
oxaliplatin together with bevacizumab before and after surgery may be an effective treatment
for liver metastases.
PURPOSE: This phase II trial is studying how well giving capecitabine and oxaliplatin
together with bevacizumab works in treating patients who are undergoing surgery for liver
metastases due to colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
Eastern Cooperative Oncology Group National Cancer Institute (NCI)